SLAMF7 and adenocarcinoma: There are some known relatively specific markers for tumoral plasma cells to distinguish from normal ones, such as CD38, CD138, G-protein Coupled Receptor 5D (GPRC5D) [15, 16] SLAMF7 (CD319), MUC1 (engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma), as well as other non-specific markers such as CD44v6, CD56, NKG2, Lewis-X, but a higher and relatively specific expression of the BCMA on these cells, currently makes it an optimal but not ideal target in CAR-T cell therapy methods.